Customer Center
Login | Register
LMNX_HEADER_RESOURCES_BLOG_640x3181

 
 
Luminex Blog

Archives

March 2015: Recent Papers Using Luminex® xMAP® Technology

March 24th, 2015 / Charles Martin

Here’s our March 2015 list of select publications from your colleagues. We’ve selected seven new papers, featuring customer-developed assays and partner kits, which we thought would be especially interesting to you.

Our bibliography helps you stay current with the success that your scientific peers are having while using Luminex® xMAP® Technology. We’ve included hyperlinks to the PubMed citation or journal sites for your convenience.

We can’t share all of the new publications with you, as your peers publish over 300 new publications each month. A complete list of over 23,000 publications using Luminex technology can be found at www.luminexcorp.com/publications.

Are there specific applications that you’d like to see us highlight?

Customer-Developed Serology Assay

Stephenson R J, Trible B R, Wang Y, Kerrigan M A, Goldstein S M,Rowland R R R. Multiplex serology for common viral infections in feral pigs (Sus scrofa) in Hawaii between 2007 and 2010. Journal of Wildlife Diseases 2015;51(1):239-243.

Cytokine Profiling

P, Jojic V, Gao T, Bhattacharya S, Angel C J L, Furman D, Shen-Orr S, Dekker C L, Swan G E, Butte A J, Maecker H T, Davis M M. Variation in the human immune system is largely driven by non-heritable influences. Cell 2015;160(1-2):37–47.

Beurskens C J, Horn J, de Boer A M T, Schultz M J, van Leeuwen E M M, Vroom M B,Juffermans N P. Cardiac arrest patients have an impaired immune response, which is not influenced by induced hypothermia. Critical Care 2014;18(4):U352-U360.

Penaloza-MacMaster P, Barber D L, Wherry E J, Provine N M, Teigler J E, Parenteau L, Blackmore S, Borducchi E N, Larocca R A, Yates K B, Shen H, Haining W N, Sommerstein R, Pinschewer D D, Ahmed R, Barouch D H. Vaccine-elicited CD4 T cells induce immunopathology after chronic LCMV infection. Science 2015;347(6219):278–283.

Shi W, Hou X, Peng H, Zhang L, Li Y, Gu Z, Jiang Q, Shi M, Ji Y, Jiang J. MEK/ERK signaling pathway is required for enterovirus 71 replication in immature dendritic cells. Virology Journal 2014;11:U12-U24.

EV71 infection promotes cytokine releases in iDCs

Figure 7. Shi et al. 2014 EV71 infection promotes cytokine releases in iDCs. The levels of cytokines in the culture supernatants of uninfected iDCs (control) and EV71-infected iDCs harvested at 2 h, 8 h and 24 h p.i. were measured by luminex fluorescence technique. The data were expressed as mean ± SE from three independent experiments and analyzed by two-way ANOVA with Bonferroni post-hoctests (**p < 0.01,***p < 0.001). This work is licensed under a Creative Commons Attribution 4.0 Generic License doi:10.1186/s12985-014-0227-7

HLA Antibody Testing

Jackson A M, Kraus E S, Orandi B J, Segev D L, Montgomery R A,Zachary A A. A closer look at rituximab induction on HLA antibody rebound following HLA-incompatible kidney transplantation. Kidney International 2015;87(2):409–416.

Telomere Length Measurement

Kibriya M G, Jasmine F, Roy S, Ahsan H,Pierce B. Measurement of telomere length: A new assay using Quantigene chemistry on a Luminex platform. Cancer Epidemiology Biomarkers & Prevention 2014;23(12):2667-2672.


 

Download the xMAP Cookbook

 

What’s New with Luminex® xMAP® Technology Partners—March 2015

March 4th, 2015 / Charles Martin

The applications of Luminex® xMAP® Technology are evolving and progressing—our partners are releasing new products for use with your xMAP instruments. We want to keep you updated on the latest information provided by some of our partners.

Life Science Research Partners:

Active Motif 

Low Cell Number Requirements Make the Histone H3 PTM Multiplex Assay Ideally Suited for Screening and Profiling
Active Motif’s Histone H3 PTM Multiplex Assay utilizes Luminex xMAP Technology to enable multiplexed analysis of histone modifications (PTMs) using extremely low cell numbers when compared to traditional methods. Current methods to study histone PTMs, including Western blot, immunohistochemistry, ELISAs, and genomewide mapping, are limited by the requirement of large numbers of fresh or frozen cells. Also, these methods are time-consuming, lack high throughput capabilities, and are limited to analysis of one or a few modifications at a time.

In contrast, the Histone H3 PTM Multiplex Assay is a high throughput/high content assay that can be completed in 3 hours and uses only nanogram quantities of sample per well, making it ideally suited for high-throughput screening and profiling of histone modification levels of clinical or compound-treated samples

The assay is sufficiently sensitive to detect histone modifications in acid extracts of cells cultured in 96-well plates with minimal cell number requirement, ranging from 500–2000 cells/well, depending on the capture bead used. The low cell number requirement makes the Histone H3 PTM Multiplex Assay a far superior choice for use in inhibitor studies and investigations involving large sample numbers.

For complete product details, please visit our website at //www.activemotif.com/luminex.

ActiveMotif

Detection of four PTMs and Histone H3 in a 5-plex assay in acid extracts of low numbers of HeLa cells.
HeLa cells were seeded as a two-fold dilution series in a 96-well plate in quadruplicate and cultured for 24 hours. Cells were then washed with PBS and acid extracts were prepared. Using the Histone H3 PTM Multiplex Assay, 1/10th of the extract from each well was tested in duplicate in a bead 5-plex. “No Lysate” background MFI was subtracted and plotted as Net MFI with standard deviation shown. The results demonstrate that PTMs can still be detected in wells seeded with as little as 625 cells per well.

 

Affymetrix (eBioscience)

ProcartaPlex® Publications
Arslan et al. from the Northewestern University in Chicago developed a novel 3D endocervical culture. It was used to monitor responses to 28-day hormone treatment. Levels of secreted cytokines and chemokines were measured with ProcartaPlex Human Cytokine/Chemokine/Growth Factor Panel 1 (45-plex).
Novel Three Dimensional Human Endocervix Cultures respond to 28-day hormone treatment
Sevim Yildiz Arslan et al.; Endocrinology | 01/30/2015

ProcartaPlex Mouse Cytokine & Chemokine Panel 1A (36-plex) was used to investigate the role of IL-1 alpha and IL-1 beta in mediating A. fumigatus infections in murine lungs by a group at the Montana State University.
IL-1α Signaling Is Critical for Leukocyte Recruitment after Pulmonary Aspergillus fumigatus Challenge
Alayna K. Caffrey, et al., PLOS Pathogens | 01/28/2015

New QuantiGene Plex Assay Application Notes
QuantiGene® Plex Assays use Luminex xMAP Technology to simultaneously measure up to 80 genes in one well. Unlike qPCR, QuantiGene Plex utilizes branched DNA signal amplification, so RNA purification, cDNA synthesis, and PCR amplification are NOT required.

Please see our new application notes:

Transcript regulation of 18 ADME genes by prototypical inducers in human hepatocytes

Determination of gene signatures to subgroup melanoma patients using novel branched DNA hybridization assays

Find us at the upcoming Society of Toxicology Annual Meeting in San Diego on March 22. See you there!

 

Bio-Rad Laboratories

Profiling Dynamic Cancer Drug Responses with BioMarker Strategies, LLC and the Bio-Plex® Multiplex Immunoassay System
Most molecularly targeted drugs today are co-approved with a companion diagnostic, but these tests don’t directly measure whether a therapy will work. For instance, when BRAF-mutant melanoma becomes resistant to BRAF inhibitors, the cancerous cells will continue expressing the mutant protein. Therefore, these patients would still be considered test-positive.

To improve on these indirect tests, a startup called BioMarker Strategies is developing PathMAP® functional profiling technology, which measures how live cancer cells respond to drugs through analysis of proteins within their key signaling pathways.

To help do that, they use Bio-Rad’s Bio-Plex assays to analyze the phosphoprotein levels in cell lysates. This highly multiplexed analysis approach is critical to BioMarker Strategies because their samples are both precious and scant.

BioMarker Strategies’ SnapPath instrument processes tissue from a solid tumor biopsy, distributes the sample among different wells for treatment, and then lyses the cells to stabilize the biomarkers for further analysis. This automation and standardization of the process is key to ensuring reproducible and reliable data.

BioMarker Strategies recently published a study demonstrating that the SnapPath system can accurately assess treatment response to a BRAF inhibitor in both cell models and clinical tumor samples. The company has begun placing their instruments at research institutions to develop the technology as a guide in drug development and treatment selection for solid tumors.

Figure2-BioRadSnapPathThe SnapPath instrument being developed by BioMarker Strategies automates the process of preparing a live tumor sample and testing its dynamic response to multiple therapies at once.

 

EMD Millipore

EMD Millipore continues to provide the best, most relevant biomarkers on magnetic bead format with these new kits:

  • MILLIPLEX® MAP Total Multi-Pathway 9 Plex Kit (Cat. No. 48-681MAG) detecting:  ERK/MAP kinase 1/2, Akt, STAT3, JNK, p70 S6 kinase, NFkB, STAT5A/B, CREB, and p38 in cell/tissue lysates. This panel complements the Phosphoprotein Multi-Pathway 9-Plex Kit (Cat. No. 48-680MAG).
  • MILLIPLEX MAP Human Angiogenesis Panel 2 (Cat. No. HANG2MAG-12K), a 20-plex kit to be used for the simultaneous quantification of any or all of the following analytes in serum, plasma, cell culture samples, and tissue homogenates/lysates: Angiostatin, sE-Selectin, Osteopontin (OPN), PDGF-AB/BB, sPECAM-1, Tenascin C, Thrombospondin-2 (TSP-2), sAXL, sc-Kit/SCFR, sEGFR, sHer2, sHer3, sHGFR/c-Met, sIL-6Rα, soluble Neuropilin-1 (sNRP-1), sTie-2, suPAR, sVEGFR1, sVEGFR2, and sVEGFR3.

For a complete list of our offering, download the MILLIPLEX MAP Analyte Quarterly!

Figure3-MILLIPLEX
For powerful multiplexed biomarker analysis, count on the experts! After years of gathering valuable tips and tricks, the multiplex assay experts at EMD Millipore have made them available to you—reserve your copy of our new technical guide: “The Power of Biomarker Analysis.”

Life Technologies

Life Technologies has recently launched some new panels.

The Human Adipokine Magnetic 15-Plex Panel for the Luminex platform is designed to simultaneously quantify IL-1β, IL-6, IL-8, IL-10, MCP-1, Leptin, SAA, HGF, Insulin, Lipocalin-2, TNF-α, BAFF, Resistin, C-peptide, and PAI-1 in serum, plasma, and tissue culture supernatant samples. Learn more here.

Figure4-LifeTech

The Human Apolipoprotein Magnetic 5-Plex Panel for the Luminex platform is designed to simultaneously quantify ApoA1, ApoB, ApoE, CRP, Adiponectin in serum, plasma, and tissue culture supernatant samples. Learn more here.

The Human Adhesion Magnetic 6-Plex Panel for the Luminex platform is designed to simultaneously quantify human ICAM, VCAM, P-selectin, E-selectin, PECAM, and PAI-1 in serum, plasma, and tissue culture supernatant samples. Learn more here.

The Human Th1/Th2/Th17 Magnetic 8-Plex Panel for the Luminex platform is designed to simultaneously quantify IL-2, IL-4, IL-5, IL-9, IL-10, IL-13, IL-17, and IFN-γ in serum, plasma, and tissue culture supernatant samples. Learn more here.

 

R&D Systems, a Bio-Techne Brand

Unlimited choices backed by the R&D Systems performance guarantee.

R&D Systems continues to deliver the largest protein multiplex for the Luminex platform with the Luminex Screening Assay. Bring your research to the next level with a menu of 244 analytes that can be selected from one panel. We offer 3–5 day turn around time to mix up to 100 analytes in the polystyrene format, or 50 analytes in the magnetic format. With unlimited combinations, R&D Systems offers the most flexibility. Why settle for limited analyte panels when you can assay any combination of your choice with the R&D Systems Luminex Screening Assay?

New Biomarkers in the R&D Systems Human Luminex Screening Assay:
CCL21/6Ckine ITIH4
CXCL14/BRAK Lumican
ESAM MSP/MST1
CD44 NCAM-1/CD56
Proteinase 3 (Myeoblastin) Galectin-9
Endostatin NT-4
ErbB2/Her2 PBEF/Visfatin
Galectin-3BP/MAC-2BP S100A8
IGFBP-rp1/IGFBP-7 S100B
IL-27 uPA/Urokinase

 

For a complete analyte list, visit the R&D Systems website at: //www.rndsystems.com/LuminexScreening.

Don’t see your analyte of interest in our complete analyte list? We’re always happy to have new product suggestions.

 

Diagnostic Partners:

One Lambda

One Lambda introduces the first FDA cleared IVD test for the detection of HLA Class I, Class II and HNA 1-5 antibodies
Transfusion-related acute lung injury (TRALI) is the leading cause of transfusion-related mortality. Defined as an acute lung injury that occurs during or within the first six hours following transfusion of a blood product,1 TRALI is fatal to 10 percent of the patients it strikes.

Several studies have been performed which have implicated the potential for antibodies to human leukocyte antigens (HLA) and human neutrophil antigens (HNA) to be involved in the mechanism for TRALI. Based on these results, multiple panels and groups have determined that testing for HLA, and HNA, antibodies would be beneficial to the blood supply and could possibly reduce the incidence of TRALI in patients. However, testing has not been widely adopted due to the lack of a commercial IVD assay.

LABScreen® Multi* receives FDA Clearance
One Lambda’s LABScreen Multi is the first FDA cleared test for the simultaneous detection of HLA Class I and Class II and HNA 1-5 antibodies. Based on the Luminex xMAP Technology, this multiplexed assay can be used to process up to 96 donors in a single run, making it ideal for transfusion centers implementing TRALI risk reduction measures.

  • Simultaneous detection of HLA Class I, Class II, and HNA 1a, 1b, 1c, 2, 3a, 3b, 4a, 5a, and 5b antibodies
  • Simple immunoassay protocol
  • Based on the high throughput Luminex platform

To learn more about LABScreen Multi, visit www.onelambda.com

  • This product is not associated with the diagnosis or treatment of TRALI.

1. Toy P, Popovsky MA, Abraham E, et al. Transfusion-related acute lung injury: definition and review. Crit Care Med 2005; 33:721.

Upcoming events

Workshops
Advanced HLA Technical WorkshopFebruary 23, 2015–February 26, 2015Green Valley Ranch | Henderson, NV

United States

» Program & RegistrationAdvanced User WorkshopMay 5, 2015–May 8, 2015One Lambda | Canoga Park, California

United States

» Registration

» ProgramEuropean Advanced User WorkshopMarch 14, 2015–March 20, 2015SANA Lisboa Hotel | Lisboa

Portugal

» Registration

» Program

 

How Do You Know if You’ve Been Vaccinated Against Measles?

February 27th, 2015 / Charles Martin

MeaslesOutbreak2014Figure from http://www.cdc.gov/measles/cases-outbreaks.html

In 2015, over 84 cases (as of January 29th, 2015) of measles have been reported.1 The majority of these cases are part of a large, ongoing outbreak linked to a Southern California amusement park. A single visitor to the park was infected with measles, and while visiting, spread measles to a number of visitors, who then continued to spread the virus.

To date, it has spread cases to over 14 states.2

Many of the employees of the amusement park and students of nearby schools have been asked to prove that they’ve been vaccinated. Over 50,000 students in Orange County, California were sent home until they could provide proof of vaccination.

How do you prove you’ve been vaccinated? Many of us were vaccinated years ago, change doctors, and lose immunization records. Once you’ve completed the vaccination series, commonly termed MMRV (for measles, mumps, rubella, and varicella-zoster), your immune system should continue to make small amounts of antibodies to each of the viruses for which the vaccine provides protection.

Generally, you can satisfy proof of immunization by providing evidence from your physician, such as an immunization record, or by having a blood test proving you have antibodies to the virus that causes measles. One of the FDA-cleared blood tests commercially available through medical providers is the BioPlex® 2200 MMRV IgG,kit, based on Luminex® xMAP® Technology, and tests for antibodies to all four of the viruses in the MMRV vaccine.

Public health agencies also use xMAP Technology to create custom epidemiological assays to study rubella-specific antibodies in populations that have high vaccination rates versus those that have lower rates of vaccination.3

Public health officials, school districts, and the amusement park are concerned that measles will be spread. Read more on how infants can be severely impacted by a measles infection.

Extra resources:

References:

  1. Measles Cases and Outbreaks. Centers for Disease Control and Prevention (Internet). Cited 2015 January. Available from: http://www.cdc.gov/measles/cases-outbreaks.html.
  2. California Department of Public Health Confirms 59 Cases of Measles. California Department of Public Health (Internet). Cited 2015 January. Available from: http://www.cdph.ca.gov/Pages/NR15-008.aspx.
  3. Smits G, Mollema L, Hahné S, de Melker H, Tcherniaeva I, van der Klis F, Berbers G. Seroprevalence of rubella antibodies in The Netherlands after 32 years of high vaccination coverage. Vaccine. 2014 Apr 1;32(16):1890-5.

February 2015: Recent Papers Using Luminex xMAP Technology

February 18th, 2015 / Charles Martin

Luminex Immunoassay Kit Finder

The xMAP® Kit Finder is a digital catalog of life science research immunoassays. With hundreds of visitors every day, the Kit Finder has become one of the most useful resources for discovering new assays and targets available from a variety of Luminex® partners.

One little known feature of Kit Finder is the ability to save a list of your favorite assays and refer back to them later. You can also share your saved lists with friends and colleagues directly from Kit Finder.

By registering or creating an account, you not only have the ability to save your favorite kits, but you can be notified of new kits and analytes and take advantage of future Kit Finder improvements.

Luminex is constantly working on adding more features to Kit Finder, and new features and functionality are coming soon. Check back for the latest updates!

All you need is your name and email address to create an account, so register on Kit Finder today!

January 2015: Recent Papers Using Luminex xMAP Technology

January 21st, 2015 / Charles Martin

Welcome to 2015. Here’s our first list of select publications from your colleagues. We’ve selected six new papers, featuring customer-developed assays and partner kits, which we thought would be especially interesting to you.

Our bibliography helps you stay current with the success that your scientific peers are having while using xMAP Technology. We’ve included hyperlinks to the PubMed citation or journal sites for your convenience.

We can’t share all of the new publications with you, as your peers publish over 300 new publications each month. A complete list of over 23,000 publications using Luminex technology can be found at www.luminexcorp.com/publications.

Are there specific applications that you’d like to see us highlight?

Affinity Proteomics Screening

Bystrom S, Ayoglu B, Haggmark A, Mitsios N, Hong M-G, Drobin K, Forsstrom B, Fredolini C, Khademi M, Amor S, Uhlen M, Olsson T, Mulder J, Nilsson P, Schwenk JM. Affinity proteomic profiling of plasma, cerebrospinal fluid, and brain tissue within multiple sclerosis. Journal of Proteome Research 2014;13(11):4607–4619.

012015-JanUpdate-Figure1Figure 1. Study overview. Over initial screening and targeted discovery analysis, protein profiles were generated in plasma from more than 170 000 immunoassays on antibody suspension bead arrays. In the screening phase, 3450 unique proteins targeted by 4595 antibodies were profiled for untargeted discovery in 22 plasma samples from MS cases and nondiseased controls. 384 antibodies toward 334 proteins, including 48 proteins that had been selected from the initial screening, were then used for a targeted discovery in plasma from a total of 172 different individuals diagnosed with MS, CIS, or OND. To confirm initial findings, we evaluated 43 protein targets in additional sample material on a 101-plex focused bead array. A set of 443 plasma samples–out of which 124 had been included in the prior stage–and 573 CSF samples were analyzed. These body fluid profiling efforts resulted in candidate targets that were subsequently evaluated by immunofluorescence analysis of post-mortem brain tissue sections from MS patients. One of these candidate antibodies, anti-IRF8, was further verified in an independent set of 50 plasma samples and characterized by Western blot analysis and epitope mapping. This work is licensed under a Creative Commons Attribution 4.0 Generic License. dx.doi.org/10.1021/pr500609e.

Autoantibody Profiling

Henjes F, Lourido L, Ruiz-Romero C, Fernandez-Tajes J, Schwenk JM, Gonzalez-Gonzalez M, Banco FJ, Nilsson P, Fuentes M. Analysis of autoantibody profiles in osteoarthritis using comprehensive protein array concepts. Journal of Proteome Research 2014;13(11):5218–5229.

Cytokine Profiling

Escudero-Perez B, Volchkova VA, Dolnik O, Lawrence P, Volchkov VE. Shed GP of ebola virus triggers immune activation and increased vascular permeability. PLoS Pathogens 2014;10(11):U412-U428.

Gastrointestinal Pathogen Detection

Beckmann C, Heininger U, Marti H, Hirsch HH. Gastrointestinal pathogens detected by multiplex nucleic acid amplification testing in stools of pediatric patients and patients returning from the tropics. Infection 2014;42(6):961–970.

Gene Expression

Misharin AV, Cuda CM, Saber R, Turner JD, Gierut AK, HainesIii GK, Berdnikovs S, Filer A, Clark AR, Buckley CD, Mutlu GM, Budinger GRS, Perlman H. Nonclassical ly6c(-) monocytes drive the development of inflammatory arthritis in mice. Cell Report 2014;9(2):591–604.

HLA Typing

Petitdemange C, Wauquier N, Jacquet JM, Theodorou I, Leroy E, Vieillard V. Association of hla class-i and inhibitory kir genotypes in gabonese patients infected by chikungunya or dengue type-2 viruses. PLoS One 2014;9(9):U1285–U1292.

Metabolic Biomarker Profiling

Gusarova V, Alexa CA, Na E, Stevis PE, Xin Y, Bonner-Weir S, Cohen JC, Hobbs HH, Murphy AJ, Yancopoulos GD, Gromada J. ANGPTL8/betatrophin does not control pancreatic beta cell expansion. Cell 2014;159(3):691–696.

December 2014: Recent Papers Using Luminex xMAP Technology

December 17th, 2014 / Charles Martin

As 2014 comes to a close, we have one last highlight of the numerous publications from our customers. We’ve selected seven new papers, featuring customer-developed assays and partner kits, which we thought would be especially interesting to you.

Our bibliography helps you stay current with the success that your scientific peers are having while using xMAP® Technology. We’ve included hyperlinks to the PubMed citation or journal sites for your convenience.

We can’t share all of the new publications with you, as your peers publish over 300 new publications each month. A complete list of over 22,000 publications using Luminex® technology can be found at www.luminexcorp.com/publications.

Are there specific applications that you’d like to see us highlight?

Gene Expression

Booher R N, Hatch H, Dolinski B M, Nguyen T, Harmonay L, Al-Assaad A-S, Ayers M, Nebozhyn M, Loboda A, Hirsch H A, Zhang T, Shi B, Merkel C E, Angagaw M H, Wang Y, Long B J, Lennon X Q, Miselis N, Pucci V, Monahan J W, Lee J, Kondic A G, Im E K, Mauro D, Blanchard R, Gilliland G, Fawell S E, Zawel L, Schuller A G,Strack P. MCL1 and BCL-xL levels in solid tumors are predictive of dinaciclib-induced apoptosis. PLoS One 2014;9(10):U160-U172.

Workflow of QuantiGene® 2.0 Plex Assay from Affymetrix used in Booher et al.Workflow of QuantiGene® 2.0 Plex Assay from Affymetrix used in Booher et al.

Cytokine Profiling

Wang L, Le Mercier I, Putra J, Chen W, Liu J, Schenk A D, Nowak E C, Suriawinata A A, Li J,Noelle R J. Disruption of the immune-checkpoint VISTA gene imparts a proinflammatory phenotype with predisposition to the development of autoimmunity. Proceedings of the National Academy of Sciences of the United States of America 2014;111(41):14846–14851.

Shepardson K M, Jhingran A, Caffrey A, Obar J J, Suratt B T, Berwin B L, Hohl T M,Cramer R A. Myeloid derived hypoxia inducible factor 1-alpha is required for protection against pulmonary Aspergillus fumigatus infection. PLoS Pathogens 2014;10(9):U458-U473.

Transplant Diagnostics

Visentin J, Guidicelli G, Bachelet T, Jacquelinet C, Audry B, Thoa N, Dubois V, Moreau J-F, Lee J-H, Couzi L, Merville P,Taupin J-L. Denatured class I human leukocyte antigen antibodies in sensitized kidney recipients: Prevalence, relevance, and impact on organ allocation. Transplantation 2014;98(7):738–744.

Customer-Developed Drug Resistance/Mutation Testing

Gu L, Kawana-Tachikawa A, Shiino T, Nakamura H, Koga M, Kikuchi T, Adachi E, Koibuchi T, Ishida T, Gao G F, Matsushita M, Sugiura W, Iwamoto A,Hosoya N. Development and customization of a color-coded microbeads-based assay for drug resistance in HIV-1 reverse transcriptase. PLoS One 2014;9(10):U837-U848.

Customer-Developed Protein Profiling

Makiya M A, Herrick J A, Khoury P, Prussin C P, Nutman T B,Klion A D. Development of a suspension array assay in multiplex for the simultaneous measurement of serum levels of four eosinophil granule proteins. Journal of Immunological Methods 2014;411:11–22.

Immunodiagnostic Testing

Huang J, Kang B H, Pancera M, Lee J H, Tong T, Feng Y, Imamichi H, Georgiev I S, Chuang G-Y, Druz A, Doria-Rose N A, Laub L, Sliepen K, van Gils M J, de la Pena A T, Derking R, Klasse P-J, Migueles S A, Bailer R T, Alam M, Pugach P, Haynes B F, Wyatt R T, Sanders R W, Binley J M, Ward A B, Mascola J R, Kwong P D,Connors M. Broad and potent HIV-1 neutralization by a human antibody that binds the gp41-gp120 interface. Nature 2014;515(7525):138-142.

November 2014: Recent Papers Using Luminex xMAP Technology

November 24th, 2014 / Charles Martin

Another month has passed and it’s time to share the highlights of the numerous publications from our customers. We’ve selected six new papers, featuring customer-developed assays and partner kits, which we thought would be especially interesting to you.

Our bibliography helps you stay current with the success that your scientific peers are having while using xMAP Technology. We’ve included hyperlinks to the PubMed citation or journal sites for your convenience.

We can’t share all of the new publications with you, as we collect over 300 new publications each month. A complete list of over 22,000 publications using Luminex technology can be found at www.luminexcorp.com/publications.

Are there specific applications that you’d like to see us highlight?

Cytokine Profiling

Gawriluk TR, Ko C, Hong X, Christenson LK, RuckerIii EB. Beclin-1 deficiency in the murine ovary results in the reduction of progesterone production to promote preterm labor. Proceedings of the National Academy of Sciences of the United States of America 2014;111(40):E4194-E4203.

Dinel A-L, Joffre C, Trifilieff P, Aubert A, Foury A, Le Ruyet P, Laye S. Inflammation early in life is a vulnerability factor for emotional behavior at adolescence and for lipopolysaccharide-induced spatial memory and neurogenesis alteration at adulthood. Journal of Neuroinflammation 2014;11:U1-U13.

Dinel et al. Journal of Neuroinflammation 2014 11:155   doi:10.1186/s12974-014-0155-xFrom Dinel et al: Lipopolysaccharide (LPS) increases cytokines expression in plasma and brain structures of postnatal day 14 (PND14) mice. Plasma concentration (pg/ml) of cytokines was measured by BioPlex 3 h after intraperitoneal (i.p.) administration of saline or LPS (100 μg/kg) in mice (A). Cytokine mRNA expression was measured by real-time rt-PCR in the hypothalamus (B), hippocampus (C), prefrontal cortex (D) and amygdala (E). Data are expressed as mean ± SEM, *P < .05, **P < .01, ***P < .001, for NaCl compared to LPS, n = 20.

 

Influenza Testing

Johnstone J, Parsons R, Botelho F, Millar J, McNeil S, Fulop T, McElhaney J, Andrew MK, Walter SD, Devereaux PJ, Malekesmaeili M, Brinkman RR, Mahony J, Bramson J, Loeb M. Immune biomarkers predictive of respiratory viral infection in elderly nursing home residents. PLoS One 2014;9(10):U173-U182.

 

HLA Testing

Kim JJ, Balasubramanian R, Michaelides G, Wittenhagen P, Sebire NJ, Mamode N, Shaw O, Vaughan R, Marks SD. The clinical spectrum of de novo donor-specific antibodies in pediatric renal transplant recipients. American Journal of Transplantation 2014;14(10):2350–2358.

 

Gene Expression

Cummings M, Sarveswaran J, Homer-Vanniasinkam S, Burke D, Orsi NM. Glyceraldehyde-3-phosphate dehydrogenase is an inappropriate housekeeping gene for normalising gene expression in sepsis. Inflammation 2014;37(5):1889–1894.

 

HPV Genotyping

Seraceni S, De Seta F, Colli C, Del Savio R, Pesel G, Zanin V, D’Agaro P, Contini C, Comar M. High prevalence of hpv multiple genotypes in women with persistent chlamydia trachomatis infection. Infectious Agents and Cancer 2014;9(U1-U7).

October 2014: Recent Papers Using Luminex xMAP Technology

October 21st, 2014 / Charles Martin

Luminex® xMAP® Technology has become an indispensable tool for tens of thousands of life science researchers. Here are six new papers, featuring customer-developed assays and partner kits, which we thought would be especially interesting to you.

Our bibliography helps you stay current with the success that your scientific peers are having while using xMAP Technology. We’ve included hyperlinks to the PubMed citation or journal site for your convenience.

A complete list of over 22,000 publications using Luminex can be found at www.luminexcorp.com/publications.

Affinity Proteomics Screening

Bachmann J, Burte F, Pramana S, Conte I, Brown BJ, Orimadegun AE, Ajetunmobi WA, Afolabi NK, Akinkunmi F, Omokhodion S, Akinbami FO, Shokunbi WA, Kampf C, Pawitan Y, Uhlen M, Sodeinde O, Schwenk JM, Wahlgren M, Fernandez-Reyes D, Nilsson P. Affinity proteomics reveals elevated muscle proteins in plasma of children with cerebral malaria. PLoS Pathogens 2014;10(4):U137-U148.

Figure 1 - October xMAP Research

FIGURE 1: Overview of affinity proteomics screening and study design.

A. Schematic overview of the affinity proteomics approach using antibody suspension bead arrays. Plasma samples were biotinylated, antibodies were coupled to color-coded magnetic beads, and both were combined for analysis. Bead identity and captured plasma proteins were then detected using a flow cytometric analyzer. B. Experimental design of study. Initial screening with 1,132 antibodies from targeted and blinded selections was performed in the discovery cohort (n=356). Data from the patient groups were compared using univariate tests and multivariate penalized regression models. Identified single proteins and multi-component protein panels discriminating the 3 disease groups were validated in the verification cohort (n=363).

Cytokine Profiling

Lynch HE, Sanchez AM, D’Souza MP, Rountree W, Denny TN, Kalos M, Sempowski GD. Development and implementation of a proficiency testing program for Luminex bead-based cytokine assays. Journal of Immunological Methods 2014;409(62–71).

Suh JM, Jonker JW, Ahmadian M, Goetz R, Lackey D, Osborn O, Huang Z, Liu W, Yoshihara E, van Dijk TH, Havinga R, Fan W, Yin Y-Q, Yu RT, Liddle C, Atkins AR, Olefsky JM, Mohammadi M, Downes M, Evans RM. Endocrinization of FGF1 produces a neomorphic and potent insulin sensitizer. Nature 2014;513(7518):436–439.

von Burg N, Chappaz S, Baerenwaldt A, Horvath E, Dasgupta SB, Ashok D, Pieters J, Tacchini-Cottier F, Rolink A, Acha-Orbea H, Finke D. Activated group 3 innate lymphoid cells promote T-cell-mediated immune responses. Proceedings of the National Academy of Sciences of the United States of America 2014;111(35):12835–12840.

Gene Expression

Riley BE, Gardai SJ, Emig-Agius D, Bessarabova M, Ivliev AE, Schuele B, Alexander J, Wallace W, Halliday GM, Langston JW, Braxton S, Yednock T, Shaler T, Johnston JA. Systems-based analyses of brain regions functionally impacted in Parkinson’s disease reveals underlying causal mechanisms. PLoS One 2014;9(8):U61-U74.

HLA Testing

Schaub S, Hoenger G, Koller MT, Liwski R, Amico P. Determinants of C1q binding in the single antigen bead assay. Transplantation 2014;98(4):387–393.

What’s New with Luminex® xMAP® Technology Partners—October 2014

October 16th, 2014 / Charles Martin

The world of xMAP® Technology is evolving and progressing—our partners are releasing new products for use with your xMAP instruments. We want to keep you updated on the latest information provided by some of our partners.

Life Science Research Partners:

 

Active Motif:

New Ab-conjugated Bead targets for use with Luminex® Histone H3 PTM Multiplex Assays:

Active Motif’s continuing expansion of modified histone targets for analysis using the Histone H3 PTM Multiplex Assay, the first epigenetic assay with multiplexing capability, now includes antibody-conjugated bead sets for H3K56ac, H3K27ac and H3T11ph histone modifications. The Histone H3 PTM Multiplex Assay enables high-throughput, high content screening of changes in histone modification levels using smaller sample amounts, and in less time and at a lower cost than traditional Western blot or immunofluorescence. The multiplexing capability is highly advantageous for screening assays because it provides the ability to interrogate both specific and off-target effects simultaneously.

Modification-specific antibody-conjugated beads are packaged individually to allow researchers to customize their assays for singleplex or multiplex analysis simply by selecting the antibody-conjugated beads for their post-translational modification (PTM) of interest. Each antibody-conjugated bead set used to capture modified histones has its own unique fluorescent label, enabling antibodies for multiple histone PTMs to be added to the same sample for multiplexing. A biotinylated reporter antibody is used to detect and measure the level of histones bound to the bead and produce a fluorescent signal following the addition streptavidin-phycoerythrin.

As the beads pass through the internal fluidics of the Luminex instrument, the fluorescent signals emitted by each bead are read to determine the bead identity and provide a readout of the streptavidin-phycoerythrin signal that is proportional to the amount of histone PTM captured by each bead set. The inclusion of Histone H3 Total Antibody-conjugated Beads into the multiplex reaction enables normalization against total H3 levels for determining relative histone PTM levels across samples.

Affymetrix (eBioscience)

QuantiGene® Plex Assay Pathway Panels

QuantiGene® Plex Assays use Luminex® xMAP® technology to simultaneously measure up to 80 genes in one well. Unlike qPCR, QuantiGene® Plex (QGP) utilizes branched DNA signal amplification, so RNA purification, cDNA synthesis, and PCR amplification are NOT required. Affymetrix now offers predesigned QGP pathway panels in the following areas:

  • Apoptosis and Autophagy
  • Cancer signaling
  • Cardiology and bone biology
  • Epigenetics
  • Inflammation and Immunology
  • Metabolism and Endocrinology
  • Neuroscience
  • Stem Cells
  • Toxicity and Drug Metabolism

Download the QGP Pathway Panel Guide here for the complete list of predesigned panels.

eBioscience launched new Isotyping panels for mouse and rat:

ProcartaPlex Mouse Antibody Isotyping Panel 2 (IgG2c included) (7 plex) Certain inbred mice strains such asC57Bl/6, C57Bl/10, SJL, and NOD with the Igh1-b allele do not have the gene for IgG2a, but instead express IgG2c. Therefore, eBioscience included IgG2c into their new ProcartaPlex Mouse Isotyping Panel 2. Analytes: IgG1, IgG2b, IgG2c, IgG3, IgA, IgE, IgM

ProcartaPlex Rat Antibody Isotyping Panel (6 plex) Analytes: IgG1, IgG2a, IgG2b, IgG2c, IgA, IgM

More new products of eBioscience:

Non-Human Primates (NHP)

ProcartaPlex NHP Cytokine/Chemokine/Growth Factor Panel (37 plex) Analytes: BDNF, BLC (CXCL13), NGF beta, Eotaxin (CCL11), FGF-2, G-CSF (CSF-3), GM-CSF, IFN alpha, IFN gamma, IL-1 beta, IL-10, IL-12p70, IL-13, IL-15, IL-17A (CTLA-8), IL-18, IL-1RA, IL-2, IL-23, IL-4, IL-5, IL-6, IL-7, IL-8 (CXCL8), IP-10 (CXCL10), I-TAC (CXCL11), MCP-1 (CCL2), MIG (CXCL9), MIP-1 alpha (CCL3), MIP-1 beta (CCL4), PDGF-BB, sCD40L, SCF, SDF-1 alpha (CXCL12a), TNF alpha, VEGF-A, VEGF-D

ProcartaPlex NHP Cytokine & Chemokine Panel (30 plex) Analytes: BLC (CXCL13), Eotaxin (CCL11), G-CSF (CSF-3), GM-CSF, IFN alpha, IFN gamma, IL-1 beta, IL-10, IL-12p70, IL-13, IL-15, IL-17A (CTLA-8), IL-18, IL-1RA, IL-2, IL-23, IL-4, IL-5, IL-6, IL-7, IL-8 (CXCL8), IP-10 (CXCL10), I-TAC (CXCL11), MCP-1 (CCL2), MIG (CXCL9), MIP-1 alpha (CCL3), MIP-1 beta (CCL4), sCD40L, SDF-1 alpha (CXCL12a), TNF alpha

ProcartaPlex NHP Growth Factor Panel (7 plex) Analytes: BDNF, FGF-2, NGF beta, PDGF-BB, SCF, VEGF-A, VEGF-D Human

Human Myokine Panel (8 plex) Analytes: BDNF, IL-6, IL-8, IL-10, IL-15, IL-1RA, LIF, TNF alpha Mouse

Mouse Myokine Panel (5 plex) Analytes: IL-6, IL-10, IL-15/IL-15R, LIF, TNF alpha

Bio-Rad

For the first time ever, the most popular biomarkers of inflammation from the TNF superfamily proteins, IFN family proteins, Treg cytokines, and MMPs can be measured in a single multiplex kit. Available in larger 24- and 37-plex screening panels and a pathway-focused Treg 12-plex panel, along with singleplex and custom configured assays. Benefits of Bio-Plex Pro Inflammation Assays include:

  • Unique and Relevant Mix of Targets—The only Luminex kit available that combines TNF superfamily proteins, IFN family proteins, Treg cytokines, and MMPs in one assay
  • Flexible Ordering Options—Two large plex inflammation screening premixed ready to use kits (37 and 24 plex), a Treg 12-plex, singleplex, and any combination of custom kits available as “you mix” and “we mix” options
  • Rapid results—Multiplex data in just 3.5 hours through the use of magnetic beads and the fastest assay protocols

Bio-Rad Bio-Plex Pro™ Human Inflammation Assays

View targets and preorder now for special pricing.

Join us on November 6th for an informative webinar: “Biomarker Profiling in Diabetes and Cardiovascular Disease.” Learn how diabetes and related metabolic conditions are linked to cardiovascular disease, which protein biomarkers are currently being studied in these conditions, and how to leverage multiplex metabolic and hormone assays to profile multiple protein biomarkers relevant to metabolic and cardiovascular diseases.

Register now for the webinar: Biomarker Profiling in Diabetes and Cardiovascular Disease.

EMD Millipore

EMD Millipore continues to provide the best, most relevant biomarkers on magnetic bead format:

  • MILLIPLEX® MAP Non-Human Primate Cytokine Panel 2 – Configurable 25-Plex ( PRCYT2MAG40K), 24-Plex Premixed (PRCYTMAG40K-PX24), 25-Plex Premixed (PRCYTMAG40K-PX25)
  • MILLIPLEX® MAP Mouse Cardiovascular Panel 2 – Configurable 9-Plex (MCVD2MAG-77K)
  • MILLIPLEX® MAP Canine Kidney Toxicity Panel 2 – Configurable 4-Plex (CKT2MAG-97K)
  • MILLIPLEX® MAP Rat Liver Injury Configurable 5-Plex (RLI1MAG-92K)
  • MILLIPLEX® MAP Rat Adipocyte Configurable 7-Plex (RADPCMAG-82K)
  • MILLIPLEX® MAP Rat Adipokine Configurable 7-Plex (RADPKMAG-80K)
  • MILLIPLEX® MAP Rat Adiponectin Single Plex Kit (RADPNMAG-81K-01)

For a complete list of our offering, download the MILLIPLEX® MAP Analyte Quarterly! For powerful multiplexed biomarker analysis, count on the experts!

The Power of Biomarker Analysis

After years of gathering valuable tips and tricks, the multiplex assay experts at EMD Millipore have made them available to you–reserve your copy of our new technical guide: “The Power of Biomarker Analysis.”

WEBINAR, November 4, 2014: Novel Multiplexed Assay Panels to Detect Kidney Injury Biomarkers in Mouse Models. Learn to:

  • Use biomarkers in drug development and safety assessment
  • Develop informative and predictive experimental models of kidney injury
  • Successfully perform multiplexed immunodetection assays

For details and to register, click here. Visit emdmillipore.com/lifesciences_webinars for upcoming and archived webinars.

LifeTechnologies

Novex® multiplex assays enable the simultaneous analysis of multiple proteins in single samples from a broad range of biological sources. Based on Luminex xMAP (multi-analyte profiling) technology, Novex multiplex assays combine the efficiencies of multiplexing with the accuracy, sensitivity, reproducibility, and simplicity of ELISA. www.lifetechnologies.com/immunoassayguide

Webinar (Recorded from September 25, 2014): Biomarker Discovery, Quantitation, and Analysis with Multiplex Immunoassays. Duration: 60 minutes.

Myriad RBM

NeuroMAP™ v. 1.0 is a quantitative, multiplexed immunoassay service measuring 36 blood-based proteins associated with neurodegenerative disorders including Alzheimer’s disease, Parkinson’s disease, and Multiple Sclerosis. Built on Myriad RBM’s robust Multi-Analyte Profiling (MAP) technology, NeuroMAP can be used as a targeted proteomics approach to help identify and characterize novel biomarker candidates for neurodegenerative drug and diagnostic development programs. Visit our website to see a list of the biomarkers included.

Webinar: Detection of Subclinical Interstitial Lung Disease: A Potential Role for Targeted Blood Biomarker Profiling

Watch this webinar to explore:


  • The rationale for early detection of Pulmonary Fibrosis
  • Phenotypic characteristics of Subclinical Interstitial Lung Disease (ILD) in at risk populations
  • A strategy to select blood biomarkers for Subclinical ILD
  • How our translational research studies can improve the diagnosis and treatment of ILD

ProtATonce

ProtATonce launches turnkey solutions for high-throughput screening (HTS). Assays for bulk use are offered via our assay development service for 500+ proteins and includes all buffers to run hundreds of plates. Our assays guarantee best performance since ProtATonce has screened 1000s antibodies and has selected the ones with maximum affinity and minimal cross-reactivity.

ProtATonce also offers an A-to-Z service that includes: cell culture, sample prep, data acquisition, and data analysis. Our A-to-Z service includes Systems Pharmacology for drug discovery that allows researchers to construct signaling pathways, identify drug mode of action, predict efficacy/toxicity and identify optimal target using Luminex assays.

R&D Systems, a Bio-Techne Brand

New Ordering Tool for Luminex Assays! We have a streamlined website tool for customizing Luminex multi-analyte assays. The tool walks you through all the important choices in designing the best assay for your research.

Luminex® xMAP® Immunoassay Kit Finder

September 2014: Recent Papers Using Luminex xMAP Technology

September 16th, 2014 / Charles Martin

Luminex® xMAP® Technology has become an indispensable tool for tens of thousands of life science researchers. Here are eight new papers, featuring customer-developed assays and partner kits, that we thought would be especially interesting to you. Our bibliography helps you stay current with the success that your scientific peers are having while using xMAP Technology. We’ve included hyperlinks to the PubMed citation or journal site for your convenience. A complete list of over 21,000 publications using Luminex can be found at www.luminexcorp.com/publications.

Cytokine Profiling

Arranz L, Sanchez-Aguilera A, Martin-Perez D, Isern J, Langa X, Tzankov A, Lundberg P, Muntion S, Tzeng Y-S, Lai D-M, Schwaller J, Skoda R C,Mendez-Ferrer S. Neuropathy of haematopoietic stem cell niche is essential for myeloproliferative neoplasms. Nature 2014;512(7512):78 – +

Giordano M, Roncagalli R, Bourdely P, Chasson L, Buferne M, Yamasaki S, Beyaert R, van Loo G, Auphan-Anezin N, Schmitt-Verhulst A-M,Verdeil G. The tumor necrosis factor alpha-induced protein 3 (TNFAIP3, A20) imposes a brake on antitumor activity of CD8 T cells. Proceedings of the National Academy of Sciences of the United States of America 2014;111(30):11115 – 11120

Jacobs E S, Persad D, Ran L, Danesh A, Heitman J W, Deng X, Cameron M J, Kelvin D J,Norris P J. A CD4(+) T cell antagonist epitope down-regulates activating signaling proteins, up-regulates inhibitory signaling proteins and abrogates HIV-specific T cell function. Retrovirology 2014;11(U1 – U16)


SeptemberxMAPTech

Multiplex detection of secreted cytokines. Secreted cytokines and chemokines following co-culture of CD4+ T cells with peptide or mock pulsed B cells were detected by multiplex assay. (A) and (B) Cytokine levels were tested in CD4+ T cell supernatants at serial time points over 18 hours with data for IFN-γ and TNF-α shown for two experiments (Ant treatment was run once). (C) Total area under the curve for secretion of each cytokine over 4 hours post-stimulation was calculated as described in Materials and Methods. Mean values from two replicate experiments are shown; error bars show SEM. (D) Percent suppression of agonist-induced cytokine suppression by addition of antagonist peptide. Suppression was calculated based on the AUC of cytokines four hours after stimulation. Dashed lines indicated the 95% confidence interval of the mean of 2 experiments, error bars show SEM. Jacobs et al. Retrovirology 2014 11:57   doi:10.1186/1742-4690-11-57

Kolokoltsova O A, Yun N E,Paessler S. Reactive astrogliosis in response to hemorrhagic fever virus: Microarray profile of Junin virus-infected human astrocytes. Virology Journal 2014;11(U1 – U13

Vande Walle L, Van Opdenbosch N, Jacques P, Fossoul A, Verheugen E, Vogel P, Beyaert R, Elewaut D, Kanneganti T-D, van Loo G,Lamkanfi M. Negative regulation of the NLRP3 inflammasome by A20 protects against arthritis. Nature 2014;512(7512):69 – +

Enzyme Activity Profiling

Bachovchin D A, Koblan L W, Wu W, Liu Y, Li Y, Zhao P, Woznica I, Shu Y, Lai J H, Poplawski S E, Kiritsy C P, Healey S E, DiMare M, Sanford D G, Munford R S, Bachovchin W W,Golub T R. A high-throughput, multiplexed assay for superfamily-wide profiling of enzyme activity. Nature Chemical Biology 2014;10(8):656 – U203

Gene Expression Profiling

Duan Q N, Flynn C, Niepel M, Hafner M, Muhlich J L, Fernandez N F, Rouillard A D, Tan C M, Chen E Y, Golub T R, Sorger P K, Subramanian A,Ma’ayan A. LINCS canvas browser: Interactive web app to query, browse and interrogate LINCS L1000 gene expression signatures. Nucleic Acids Research 2014;42(W1):W449 – W460

Wawer M J, Li K, Gustafsdottir S M, Ljosa V, Bodycombe N E, Marton M A, Sokolnicki K L, Bray M-A, Kemp M M, Winchester E, Taylor B, Grant G B, Hon C S-Y, Duvall J R, Wilson J A, Bittker J A, Dancik V, Narayan R, Subramanian A, Winckler W, Golub T R, Carpenter A E, Shamji A F, Schreiber S L,Clemons P A. Toward performance-diverse small-molecule libraries for cell-based phenotypic screening using multiplexed high-dimensional profiling. Proceedings of the National Academy of Sciences of the United States of America 2014;111(30):10911 – 10916